In the combination therapy literature reviewed herein one case of cancer (target tissue not specified) was reported in a retrospective observational study of exenatide BID used in combination with insulin in a study of obese patients with a long duration of diabetes (average 15.1 years) 16. The gene discussed is INS; the disease is cancer.